Regulations.gov document
Attachment 3 Proposed label for Solifenacin Succinate Oral Solution re Suitability…
Supporting & Related Material · FDA-2021-P-0567 · posted Jul 7, 2021
Key facts
| Document ID | FDA-2021-P-0567-0005 |
|---|---|
| Title | Attachment 3 Proposed label for Solifenacin Succinate Oral Solution re Suitability Petition from M A Pharmaceutical Consulting Inc |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2021-P-0567 |
| Posted | Jul 7, 2021 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: